ImmuPharma plc (LON:IMM – Get Free Report) shares rose 168.7% on Thursday . The stock traded as high as GBX 3.80 ($0.05) and last traded at GBX 3.22 ($0.04). Approximately 61,345,711 shares changed hands during trading, an increase of 451% from the average daily volume of 11,133,673 shares. The stock had previously closed at GBX 1.20 ($0.01).
ImmuPharma Stock Up 175.0 %
The firm has a market cap of £13.74 million, a P/E ratio of -330.00 and a beta of 1.53. The business’s 50 day moving average is GBX 1.36 and its two-hundred day moving average is GBX 1.63.
ImmuPharma Company Profile
ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics. Its peptide-based therapeutics are used in the therapy areas of autoimmunity and inflammation, and anti-infectives. The company's lead product candidate is the Lupuzor, an autophagy immunomodulator, which is in Phase III clinical trial for the treatment of lupus, an autoimmune chronic inflammatory disease.
Read More
- Five stocks we like better than ImmuPharma
- What is the Euro STOXX 50 Index?
- Shutterstock and Getty: A $3.7 Billion Visual Content Giant
- Compound Interest and Why It Matters When Investing
- 3 Smart Picks: Discounted Stocks for Savvy Investors
- Stock Average Calculator
- NVIDIA Deal Ignites Aurora Stock’s Explosive Potential
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
